IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight DelveInsight's 'IgA Nephropathy Pipeline Insight 2026' report provides comprehensive global ...
Finding a kidney donor for IgA nephropathy is a journey, but it’s possible. Here’s what to know about living donation, ...
IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...
VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics ...
Please provide your email address to receive an email when new articles are posted on . NephCure will have a free, virtual town hall to bring attention to IgA nephropathy. The nonprofit will also ...
Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase II trial revealed that felzartamab, an investigational ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...
You can exercise with IgAN safely and effectively. Here are workouts to consider, how to get started, and when to seek ...
Explore KDIGO 2025 IgA nephropathy shifts: treat earlier at proteinuria >0.5 g/day, dual-pathway therapy aims to preserve GFR. Welcome back to another AJMC Insights series. In this episode titled, ...